VIR250516P2500
- 0.05
- 0.000.00%
Vir Biotechnology Newsroom
Press Release: Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025
The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.
A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.
Express News | Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (Easl) Congress 2025
Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025
Vir Biotechnology Analyst Ratings
Goldman Sachs Maintains Vir Biotechnology(VIR.US) With Buy Rating, Cuts Target Price to $21
Prelude to increased tariffs? The Trump administration has initiated a Section 232 investigation into pharmaceuticals and Semiconductors.
① The USA government disclosed on Monday that it has launched an investigation into the impact of imported Pharmaceuticals and Semiconductors on National Security; ② This is widely seen as a prelude to imposing tariffs on prescription drugs and Semiconductors, and it could further escalate the trade war initiated by the USA.
Vir Biotechnology CEO & Director Marianne De Backer Sells 33% Of Holding
Vir Biotechnology Insider Sold Shares Worth $474,239, According to a Recent SEC Filing
Vir Biotechnology, Inc. (NASDAQ:VIR) Is Favoured by Institutional Owners Who Hold 53% of the Company
Crisis and Redemption: The Darkest Moment and Dawn of the Vaccine Industry.
The vaccine Industry is currently facing challenges, but its fate is not simply a one-way decline.
Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $20
Vir Biotechnology Enrolls First Patient In Phase 3 ECLIPSE Registrational Program For Chronic Hepatitis Delta
Express News | Vir Biotechnology Enrolls First Patient in Phase 3 Eclipse Registrational Program for Chronic Hepatitis Delta
Vir Biotechnology's Strategic Advancements and Financial Health Justify Buy Rating
Vir Biotechnology, Inc. (NASDAQ:VIR) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Barclays Maintains Vir Biotechnology(VIR.US) With Buy Rating, Raises Target Price to $31
Barclays Maintains Overweight on Vir Biotechnology, Raises Price Target to $31
Vir Biotechnology Price Target Maintained With a $110.00/Share by HC Wainwright & Co.